Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Sartorius Stedim Biotech announces French government-backed R&D project

Sartorius Stedim Biotech (SSB) has announced a €23m research and development (R&D) programme with funding from local government bodies La Region Provence-Alpes-Cote d’Azur and la Metropole Aix-Marseille Provence, France.

Samsung Bioepis to take on J&J with FDA approved Remicade biosimilar

Samsung Bioepis’ Renflexis has become the second biosimilar of rheumatoid arthritis biologic Remicade (infliximab) to be recommended for approval in the US.

A cracking new method: Valneva and Bavarian Nordic’s hen egg alternative

Valneva and Bavarian Nordic have entered a commercial agreement to develop cell-based vaccines using production methods that are faster and cheaper than methods that use hen’s eggs. 

UK MHRA announces pre-election quiet period

Tory Prime Minister Teresa May’s decision to call a snap election to stymie opposition of her stewardship of Brexit will see the MHRA limit communication to essential information.

BioInvent buys Merck single-use tech to up mAb capacity

BioInvent International AB has acquired a range of different single-use bioreactors from Germany’s Merck to up monoclonal antibody (mAb) capacity at its plant in Lund, Sweden.


Hey big vendor... Is bioprocessing consolidation good for the end-user?

Price hikes and lack of innovation, or better buying power and end-to-end services? Experts are split on supplier M&A and its effect on biomanufacturers.

1st Stem Cell Community day in Germany

For stem cells 'the process is the product,' says Pluristem

Manufacturing tweaks have severe effects on the quality and yield of stem cells, says Pluristem which has successfully scaled-up production through a decade of process development evolution.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...